Evaluation of the efficiency of treatment with the domestic drug “Promisan” of patients with cervical intraepithelial neoplasia grade I

Abstract

BACKGROUND: At present cervical cancer (CC) is one of the most common malignancies in women. The prevention of cervical cancer is early diagnosis and timely treatment of precancerous processes, which include cervical intraepithelial neoplasia (CIN).
 
 AIM: To evaluate the clinical efficacy of treatment of patients with CIN I with the use of domestic drug Promisan.
 MATERIALS AND METHODS: A total of 58 patients with CIN I were studied. They were divided into 4 groups (group I and group II are the treatment groups, group III and group IV are control groups). Group I included 16 patients who received treatment with the drug Promisan in conservative treatment. Group II included 18 patients who received complex treatment consisting of radio-wave excision of the cervix followed by the administration of Promisan. Group III included 14 patients with expectant treatment (without Promisan) and Group IV included 10 patients who underwent radio-wave excision of the cervix with subsequent dynamic observation (without Promisan).
 RESULTS: Improvement in the CIN regression indices of the 1st degree, improvement in colposcopic data and regression / elimination of the human papillomavirus were revealed in a greater percentage in patients who received Promisan as monotherapy and as part of complex therapy compared to the control groups.
 CONCLUSIONS: The results of the study make it possible to recommend Promisan for the prevention of cervical cancer in patients with dysplastic processes.